Reuters logo
2 months ago
BRIEF-BerGenBio starts randomised phase I/II trial of selective AXL inhibitor BGB324
May 22, 2017 / 6:05 AM / 2 months ago

BRIEF-BerGenBio starts randomised phase I/II trial of selective AXL inhibitor BGB324

1 Min Read

May 22 (Reuters) - BERGENBIO ASA

* BERGENBIO ANNOUNCES START OF RANDOMISED PHASE I/II TRIAL ASSESSING SELECTIVE AXL INHIBITOR BGB324 IN COMBINATION WITH CURRENT THERAPIES IN MELANOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below